PARP inhibitors

step up climb ladder sky hang on rung
Biotech

Merck inks $169M PARP1 deal, escalating challenge to AstraZeneca

The outlay, which is backed by up to 1.4 billion euros in milestones, strengthens Merck’s hand in a cancer field targeted by AstraZeneca and Gilead.
Nick Paul Taylor Oct 30, 2023 8:40am
Breast Cancer Cells

First-in-class drug halts breast and ovarian cancer in mice

Oct 27, 2023 7:45am
handshake deal shake hand arrows ok yes

Ariceum bolsters radiopharma efforts with Theragnostics buy

Jun 1, 2023 10:35am